271 related articles for article (PubMed ID: 33410494)
1. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.
Zhang X; Zhou S; Wu C; Li M; Wang Q; Zhao Y; Zeng X
Rheumatology (Oxford); 2021 Jul; 60(7):e227-e228. PubMed ID: 33410494
[No Abstract] [Full Text] [Related]
2. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
3. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
Nandy A; Gaïni S; Sore P
Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
[No Abstract] [Full Text] [Related]
4. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody.
Honda M; Moriyama M; Kondo M; Kumakura S; Sumita Y; Murakawa Y
Scand J Rheumatol; 2020 May; 49(3):244-246. PubMed ID: 31571515
[No Abstract] [Full Text] [Related]
5. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
8. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
[No Abstract] [Full Text] [Related]
9. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody.
Zou J; Li T; Huang X; Chen S; Guo Q; Bao C
Ann Rheum Dis; 2014 Aug; 73(8):1591-3. PubMed ID: 24739327
[No Abstract] [Full Text] [Related]
11. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
[TBL] [Abstract][Full Text] [Related]
12. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
Chan CWS; Chung HY; Lau CS; Tsang HHL
Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
[TBL] [Abstract][Full Text] [Related]
14. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
Tokunaga K; Hagino N
Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
[TBL] [Abstract][Full Text] [Related]
15. Potential inhibition of development of rapidly progressive interstitial lung disease by prompt and sufficient immunosuppressive treatment in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Shu E; Kanoh H; Murakami A; Seishima M
J Dermatol; 2017 May; 44(5):e91-e92. PubMed ID: 27774665
[No Abstract] [Full Text] [Related]
16. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
18. Rapidly progressive interstitial lung fibrosis in a patient with amyopathic dermatomyositis and anti‑MDA5 antibodies.
Górka J; Szczeklik W; Włudarczyk A; Łoboda P; Chmura Ł; Musiał J
Pol Arch Med Wewn; 2015; 125(9):685-6. PubMed ID: 26200801
[No Abstract] [Full Text] [Related]
19. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
